Examining the Effectiveness of Multidisciplinary Care Teams in Improving Outcomes for Breast Cancer Patients

NCT06856876 | Completed

• 1 other identifier: HMCKP2
• Study Type: interventional
• Target: 73
• Locations: 1 country
• Sites: 1

Brief Summary

To compare clinical outcomes, patient-reported measures (PROMs), and healthcare utilization between standard care with or without an MDCT in a cohort of women treated for breast cancer.

Conditions

Breast Cancers; Breast Cancer Female; Breast Cancer Stage I

Keywords

Breast Cancer; MDCT; Disease free survival; Quality of life; outcome

Outcome Measures

Primary Outcomes (2)

• Disease-Free Survival (DFS)

  Time from the start of treatment to the first occurrence of disease relapse, progression, or death from any cause.

  24 months (measured at 6, 12, 18, and 24 months)

• Overall survival

  Time from the start of treatment until death from any cause.

  24 months (measured at 6, 12, 18, and 24 months)

Secondary Outcomes (2)

• Recurrence rate

  24 months (measured at 6, 12, 18, and 24 months)

• Complication rate

  24 months (measured at 6, 12, 18, and 24 months)

Study Arms (2)

MDCT (Group A)

EXPERIMENTAL

Participants receive multidisciplinary care team (MDCT) treatment, including personalized treatment plans developed by oncologists, radiologists, and surgeons.

Other: Multidisciplinary Care Team (MDCT) Approach

Standard Therapy (Group B)

ACTIVE COMPARATOR

Participants receive standard care for breast cancer according to the current institutional protocols.

Other: Standard Breast Cancer Therapy

Interventions

Multidisciplinary Care Team (MDCT) Approach OTHER

A personalized breast cancer treatment plan developed through regular case discussions by a team of radiologists, oncologists, and surgeons. The MDCT coordinates patient support services and tracks treatment progress according to evidence-based guidelines.

Also known as: MDCT

MDCT (Group A)

Standard Breast Cancer Therapy OTHER

Breast cancer treatment provided according to the institutional protocols at Hayatabad Medical Complex, including standard surgery, chemotherapy, and/or radiotherapy as clinically indicated.

Also known as: Standard Therapy

Standard Therapy (Group B)

Eligibility Criteria

• Age: 18 Years - 70 Years
• Gender Eligibility Details: Only biologically female patients diagnosed with breast cancer are eligible to participate
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All female patients, diagnosed with breast cancer

You may not qualify if:

• Previous treatment for breast cancer, concurrent enrollment in another clinical research, and serious medical conditions that could affect study outcomes

Sponsors & Collaborators

• Yousaf Jan: lead

Study Sites (1)

Hayatabad Medical Complex

Peshawar, KPK, 25000, Pakistan

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Patient Care Team; Standard of Care

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Patient Care Management; Health Services Administration; Quality Indicators, Health Care; Quality of Health Care; Health Care Quality, Access, and Evaluation

Study Officials

• Yousaf Jan, MBBS, FCPS, FRCS, MRCS, ECFMG

  Hayat Abad Medical Complex, Peshawar

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: February 26, 2025
• First Posted: March 4, 2025
• Study Start: May 1, 2021
• Primary Completion: April 30, 2024
• Study Completion: April 30, 2024
• Last Updated: March 7, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)